Zhong Yuan Bio-Technology Holdings Ltd

General Information
Business:

(Note: This is NOT an IPO. This is a micro-cap NASDAQ uplisting from the OTC Market, where the company’s stock traded under the symbol “ZHYBF” and closed on Wednesday, Oct. 26, 2022, at $2.37. In this public offering in connection with the NASDAQ uplisting: The company will offer an undisclosed number of shares and the selling stockholder will offer an additional undisclosed number of shares, according to the F-1 filing dated Oct. 25, 2022. The company will not receive any proceeds from the sale of the selling stockholder’s shares.) 

Zhong Yuan Bio-Technology Holdings Limited is the Cayman Islands-incorporated holding company, which is offering the shares in this public offering.

We do business through our sole operating subsidiary, Bao Feng, which conducts business operations in China.

Bao Feng is in the business of nervonic acid research, the development of nervonic acid-based herbal and chemical drugs, and the sale of health supplements containing nervonic acid.

Nervonic acid is a long chain unsaturated omega 9 fatty acid that is an important component in myelin biosynthesis in the central and peripheral nervous system. Myelin insulates nerve cell axons to increase the speed at which information (encoded as an electrical signal) travels from one nerve cell body to another or from a nerve cell to another type of cell in the body. It is thought that nervonic acid may enhance brain function and prevent demyelination of nerve cells, and that, therefore, it may be effective in retaining or improving the health of the brain, for example in preventing or ameliorating attention-deficit hyperactive disorder (“ADHD”) in children, Alzheimer’s disease and mental degradation in the elderly and cerebrovascular disease, as well as promoting normal brain development in premature infants. The role of nervonic acid is also being studied with respect to psychotic illnesses, such as schizophrenia.

Bao Feng extracts the nervonic acid that it uses in its products from the seeds of the Acer truncatum tree, a type of maple tree native to northern China, Mongolia and Korea.

Bao Feng intends to expand its product line by building factories for purification of nervonic acid for medical level product usage.

Bao Feng is in the process of developing early screening kits for brain white matter signal abnormalities, Parkinson’s disease and ischemic strokes. It is in the clinical trial stage. After completion of clinical trials, Bao Feng will apply to the Ministry of Health of the PRC for an innovation Class III product registration certificate and related business operation license in China for the production and sale of domestic disposable medical devices. It intends to distribute its innovation Class III products to major clinics and hospitals through domestic distributors, as well as through direct sales to its partner hospitals and other medical institutions.

**Use of net proceeds from this offering: (i) research and development of an in vitro diagnosis kit for early screening of neurological diseases; (ii) research and development of new drugs for neurological diseases, and (iii) working capital and other general corporate purposes.

**Note: Revenue and net loss figures are for the year ended March 31, 2022.

Industry: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Employees: 24
Founded: 2012
Contact Information
Address Suite 901, Tesbury Centre 28 Queen’s Road East Wanchai, Hong Kong
Phone Number + 852 2919-8916
Web Address http://www.zhybiotech.com/
View Prospectus: Zhong Yuan Bio-Technology Holdings Ltd
Financial Information
Market Cap $40.0mil
Revenues $2.33 mil (last 12 months)
Net Income $-1.13 mil (last 12 months)
IPO Profile
Symbol TBA
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $15.0 mil
Manager / Joint Managers Revere Securities
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change